Listing of Claims:

1. Use of temocillin, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an intestinal disorder in a subject experiencing adherent invasive *E. coli* (AIEC) overgrowth of the intestine.

2. The use of Claim 1, wherein the intestinal disorder is selected from irritable bowel syndrome (IBS) (e.g., diarrhea-associated irritable bowel syndrome (d-IBS), irritable bowel syndrome with constipation (c-IBS), alternating constipating and diarrhea irritable bowel syndrome), Crohn's disease, traveler's diarrhea, colitis, ulcerative colitis, pouchitis, and diverticulitis.

3. The use of Claim 1 or 2, wherein the intestinal disorder is Crohn's disease.

4. The use of any one of Claims 1 to 3, wherein the medicament comprises a pharmaceutically acceptable salt of temocillin.

5. The use of any one of Claims 1 to 4, wherein the medicament is to be administered orally.

6. Use of temocillin, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for modulating adherent invasive *E. coli* (AIEC) overgrowth in a subject.

7. The use of Claim 6, wherein the AIEC overgrowth is in the subject’s intestine.

8. The use of Claim 6 or 7, wherein the subject has an intestinal disorder.

9. The use of any one of Claims 6 to 8, wherein the subject has an intestinal disorder selected from irritable bowel syndrome (IBS) (e.g., diarrhea-associated irritable bowel syndrome (d-IBS), irritable bowel syndrome with constipation (c-IBS), alternating constipating and diarrhea irritable bowel syndrome), Crohn's disease, traveler's diarrhea, colitis, ulcerative colitis, and diverticulitis.

10. The use of any one of Claims 6 to 9, wherein the subject has Crohn's disease.

11. The use of any one of Claims 6 to 10, wherein the modulation comprises a reduction in AIEC overgrowth.

12. The use of any one of Claims 6 to 11, wherein the medicament is to be administered orally.

13. Use of temocillin, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for reducing intestinal inflammation caused by adherent invasive *E. coli* (AIEC) overgrowth in a subject.

14. The use of Claim 13, wherein the subject has Crohn’s disease.

15. Use of temocillin, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for reducing one or more of diarrhea, fever, fatigue, abdominal pain and cramping, weight loss, and anemia in a subject having Crohn's disease, wherein the medicament is to be administered orally; and wherein the subject is experiencing adherent invasive *E. coli* (AIEC) overgrowth of the intestine.

16. The use of any one of Claims 13 or 14, wherein the medicament is to be administered orally.